Anti-podoplanin antibody
View Patent ↗Object of the present invention is to provide various anti-podoplanin antibodies useful as a drug or reagent. The present invention provides an anti-podoplanin antibody or antigen-binding fragment thereof, each having an epitope in any of the following regions in the amino acid sequence of podoplanin represented by SEQ ID NO: 1: (i) from position 56 to position 80, (ii) from position 81 to position 103, (iii) from position 81 to position 88, and (iv) from position 25 to position 57.
1. An anti-podoplanin antibody or antigen-binding fragment thereof, comprising one of the following three sets of CDRs:
(1)
(SEQ ID NO: 2)
a heavy chain CDR1: GYTFTSYTIH;
(SEQ ID NO: 3)
a heavy chain CDR2: YINPGSGYTNYNEKFQD;
(SEQ ID NO: 4)
a heavy chain CDR3: WDRGY;
(SEQ ID NO: 5)
a light chain CDR1: RSSQTIVHSNGNTYLE;
(SEQ ID NO: 6)
a light chain CDR2: KVSNRFS;
and
(SEQ ID NO: 7)
a light chain CDR3: FQGSHVPYT,
(2)
(SEQ ID NO: 14)
a heavy chain CDR1: GFTFSGFGMH;
(SEQ ID NO: 15)
a heavy chain CDR2: YISSVSSRIYYADTVKG;
(SEQ ID NO: 16)
a heavy chain CDR3: EQTGPAWFAY;
(SEQ ID NO: 17)
a light chain CDR1: RSSRNIVQSTGNTYLE;
(SEQ ID NO: 18)
a light chain CDR2: KVSNRFS;
and
(SEQ ID NO: 19)
a light chain CDR3: FQGSHVPPWT,
and
(3)
(SEQ ID NO: 71)
a heavy chain CDR1: GFSVTSYGIH;
(SEQ ID NO: 72)
a heavy chain CDR2: VIWTSGNTNYNSALMS;
(SEQ ID NO: 73)
a heavy chain CDR3: EDYYGYAMDY;
(SEQ ID NO: 74)
a light chain CDR1: RSSQSLLYSNGKTYLN;
(SEQ ID NO: 75)
a light chain CDR2: LVSKLDS;
and
(SEQ ID NO: 76)
a light chain CDR3: VQGTHFPWT.
2. The anti-podoplanin antibody or antigen-binding fragment thereof according to claim 1 , comprising:
a heavy chain having an amino acid sequence represented by SEQ ID NO: 26 or 63 and a light chain having an amino acid sequence represented by SEQ ID NO: 27.
3. The anti-podoplanin antibody or antigen-binding fragment thereof according to claim 1 , comprising:
a heavy chain having an amino acid sequence represented by SEQ ID NO: 30 or 67 and a light chain having an amino acid sequence represented by SEQ ID NO: 31.
4. An anti-podoplanin antibody or antigen-binding fragment thereof, comprising:
a heavy chain having an amino acid sequence represented by SEQ ID NO: 78 and a light chain having an amino acid sequence represented by SEQ ID NO: 77.
5. The anti-podoplanin antibody or antigen-binding fragment thereof according to claim 1 , wherein the anti-podoplanin antibody or antigen-binding fragment specifically binds podoplanin from a cancer cell, wherein the cancer is selected from the group consisting of malignant brain tumor, malignant mesothelioma, testicular tumor, ovarian cancer, and squamous cell cancer.
6. A pharmaceutical composition comprising the anti-podoplanin antibody or antigen-binding fragment thereof according to claim 1 .
7. The pharmaceutical composition according to claim 1 , and further comprising a substance having an anti-cancer activity bound to the anti-podoplanin antibody or antigen-binding fragment thereof.
8. A method for treating a subject of a cancer selected from the group consisting of malignant brain tumor, malignant mesothelioma, testicular tumor, ovarian cancer, and squamous cell cancer, which comprises administering to the subject the pharmaceutical composition according to claim 7 .
9. The anti-podoplanin antibody or antigen-binding fragment thereof according to claim 1 , wherein the anti-podoplanin antibody or antigen-binding fragment specifically binds podoplanin from a cancer cell, wherein the cancer is selected from the group consisting of malignant brain tumor, malignant mesothelioma, testicular tumor, ovarian cancer, and squamous cell cancer.
10. A pharmaceutical composition comprising the anti-podoplanin antibody or antigen-binding fragment thereof according to claim 1 .
11. The pharmaceutical composition according to claim 10 , and further comprising a substance having an anti-cancer activity bound to the anti-podoplanin antibody or antigen-binding fragment thereof.
12. A method for treating a subject of a cancer selected from the group consisting of malignant brain tumor, malignant mesothelioma, testicular tumor, ovarian cancer, and squamous cell cancer, which comprises administering to the subject the pharmaceutical composition according to claim 11 .